Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 15/20 | 0.70 |
| ▸ | SLC5A2 | P31639 | 10/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.70 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.70 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asebotin SCHEMBL10429626 | 0.86 | SLC5A1 (0.84) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| Phlorizin SCHEMBL113699 | 0.82 | SLC5A1 (1.00) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| Phlorizin SCHEMBL2826870 | 0.82 | SLC5A1 (1.00) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| Phlorizin SCHEMBL17290 | 0.82 | SLC5A1 (1.00) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| Phlorizin SCHEMBL22022720 | 0.82 | SLC5A1 (1.00) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| Phlorizin SCHEMBL23802544 | 0.82 | SLC5A1 (1.00) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| Phlorizin SCHEMBL16421567 | 0.82 | SLC5A1 (1.00) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| Phlorizin SCHEMBL18058585 | 0.82 | SLC5A1 (1.00) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL110262 | 0.82 | SLC5A1 (0.81) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL1144758 | 0.82 | SLC5A1 (0.81) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | claimed |
| WO-2023187599-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | DIDENKO KIRILL (MX) | 2023-10-05 | — | — | WO | claimed |
| WO-2023037254-A1 | METHODS AND COMPOUNDS FOR TREATING CORONAVIRIDAE VIRUS INFECTIONS | DIDENKO KIRILL (MX) | 2023-03-16 | — | — | WO | claimed |
| EP-4203902-B1 | HAIR CARE COMPOSITION WITH A ANTIDANDRUFF EFFECT | HENKEL AG & CO KGAA (DE) | 2026-03-11 | — | — | EP | disclosed |
| EP-3952832-B1 | NATURAL CONDITIONING SHAMPOO | HENKEL AG & CO KGAA (DE) | 2025-09-10 | — | — | EP | disclosed |
| EP-3952831-B1 | FAST RINSE SHAMPOO | HENKEL AG & CO KGAA (DE) | 2025-09-10 | — | — | EP | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4166128-B1 | LEAVE-IN HAIR CARE EMULSION | HENKEL AG & CO KGAA (DE) | 2025-03-12 | — | — | EP | disclosed |
| EP-4504133-A1 | ANTIDANDRUFF SHAMPOO | Henkel AG & Co. KGaA (DE) | 2025-02-12 | — | — | EP | disclosed |
| EP-4504135-A1 | HAIR TREATMENT COMPOSITIONS HAVING ANTIDANDRUFF ACTION | Henkel AG & Co. KGaA (DE) | 2025-02-12 | — | — | EP | disclosed |
| EP-4496557-A1 | MEANS FOR OXIDATIVELY DYEING KERATIN FIBRES, CONTAINING AT LEAST ONE OXIDATION DYE PRECURSOR OF THE DEVELOPER TYPE, ISATIN AND AT LEAST ONE DETERMINED COMPLEXING AGENT | Henkel AG & Co. KGaA (DE) | 2025-01-29 | — | — | EP | disclosed |
| CN-115844895-A | Use of an emiritone compound for the preparation of a medicament for the treatment of central nervous system cancer | 昂克希尔迪克斯有限公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2023037254-A1 | METHODS AND COMPOUNDS FOR TREATING CORONAVIRIDAE VIRUS INFECTIONS | DIDENKO KIRILL (MX) | 2023-03-16 | — | — | WO | disclosed |
| CN-109311980-B | G protein-coupled receptor (GPCR) modulation by emilienone (IMIPRIDONES) | 昂克希尔迪克斯有限公司 | 2023-01-17 | — | — | CN | disclosed |
| EP-2107902-B2 | COSMETIC COMPOSITION CONTAINING ARGAN OIL AND SHEA BUTTER | HENKEL AG & CO KGAA (DE) | 2022-11-23 | — | — | EP | disclosed |
| EP-3998059-A9 | MILD PREPARATIONS AS CLEANING OR CARE COMPOSITIONS FOR REMOVING CARBOHYDRATES OR STAINS | Perfect Ideas GmbH (CH) | 2022-09-28 | — | — | EP | disclosed |
| EP-3463271-B1 | GENTLE AGENTS AND METHODS FOR OXIDATIVE DYEING USING SELECTED DICARBOXYLIC ACIDS | HENKEL AG & CO KGAA (DE) | 2022-07-27 | — | — | EP | disclosed |
| EP-3998059-A1 | MILD PREPARATIONS AS CLEANING OR CARE COMPOSITIONS FOR REMOVING CARBOHYDRATES OR STAINS | Perfect Ideas GmbH (CH) | 2022-05-18 | — | — | EP | disclosed |
| WO-2022042979-A1 | HAIR TREATMENT COMPOSITIONS HAVING ANTIDANDRUFF ACTION | HENKEL AG & CO. KGAA (DE) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | SLC5A1 1001/4885SLC5A2 261/4885HPGD 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.